Alliancebernstein L.P. Nektar Therapeutics Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Nektar Therapeutics stock. As of the latest transaction made, Alliancebernstein L.P. holds 49,200 shares of NKTR stock, worth $43,296. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,200

Previous 49,200 -0.0%

Holding current value

$43,296

Previous $61,000 3.28%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.9 - $1.83 $44,280 - $90,036	49,200 New	49,200 $61,000
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $167,614 - $824,978	-261,898 Reduced 55.22%	212,360 $148,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $1.55 Million - $3.28 Million	-765,596 Reduced 61.75%	474,258 $1.07 Million
Q3 2022 Nov 15, 2022	SELL	$3.04 - $5.14 $3.32 Million - $5.61 Million	-1,091,004 Reduced 46.81%	1,239,854 $3.97 Million
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $4.25 Million - $8.27 Million	1,341,141 Added 135.51%	2,330,858 $8.86 Million
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $3.61 Million - $11.9 Million	868,027 Added 713.31%	989,717 $5.34 Million
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $1.68 Million - $2.86 Million	-155,230 Reduced 56.06%	121,690 $1.64 Million
Q3 2021 Nov 10, 2021	SELL	$13.07 - $18.84 $29,851 - $43,030	-2,284 Reduced 0.82%	276,920 $4.97 Million
Q2 2021 Jul 30, 2021	SELL	$16.52 - $20.4 $65,914 - $81,396	-3,990 Reduced 1.41%	279,204 $4.79 Million
Q1 2021 May 06, 2021	BUY	$16.56 - $25.46 $104,659 - $160,907	6,320 Added 2.28%	283,194 $5.66 Million
Q4 2020 Feb 08, 2021	SELL	$15.77 - $19.03 $86,419 - $104,284	-5,480 Reduced 1.94%	276,874 $4.71 Million
Q3 2020 Nov 12, 2020	SELL	$16.59 - $24.79 $81,639 - $121,991	-4,921 Reduced 1.71%	282,354 $4.68 Million
Q2 2020 Aug 13, 2020	SELL	$16.86 - $23.44 $316,462 - $439,968	-18,770 Reduced 6.13%	287,275 $6.65 Million
Q1 2020 May 14, 2020	SELL	$14.47 - $27.96 $26,769 - $51,726	-1,850 Reduced 0.6%	306,045 $5.46 Million
Q4 2019 Feb 18, 2020	BUY	$15.87 - $23.12 $609,328 - $887,692	38,395 Added 14.25%	307,895 $6.65 Million
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $4,464 - $9,575	264 Added 0.1%	269,500 $4.91 Million
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $200,043 - $234,243	6,453 Added 2.46%	269,236 $9.58 Million
Q1 2019 May 14, 2019	SELL	$31.58 - $46.35 $1,484 - $2,178	-47 Reduced 0.02%	262,783 $8.83 Million
Q4 2018 Feb 13, 2019	BUY	$30.43 - $56.65 $181,667 - $338,200	5,970 Added 2.32%	262,830 $8.64 Million
Q3 2018 Nov 08, 2018	SELL	$46.46 - $68.49 $62,070 - $91,502	-1,336 Reduced 0.52%	256,860 $15.7 Million
Q2 2018 Aug 13, 2018	SELL	$46.25 - $104.45 $8.3 Million - $18.7 Million	-179,445 Reduced 41.0%	258,196 $12.6 Million
Q1 2018 May 14, 2018	BUY	$57.4 - $108.44 $10 Million - $18.9 Million	174,135 Added 66.08%	437,641 $46.5 Million
Q4 2017 Feb 13, 2018	BUY	$23.02 - $60.5 $742,832 - $1.95 Million	32,269 Added 13.95%	263,506 $15.7 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $4.11 Million - $5.55 Million	231,237	231,237 $5.55 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $165M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Nektar Therapeutics Transaction History